Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2009

View Archived Issues

Early clinical data on novel cancer therapeutics disclosed at ASCO

Vertex claims inhibitors of voltage-gated sodium channels

Kyowa Hakko Kirin presents novel glucocorticoid receptor ligands

Bristol-Myers Squibb describes SERT and NK1R antagonists

XenoPort reports results from phase II arbaclofen placarbil trial

Preclinical, phase I and phase II data on BIM-23A760 presented

Meta-analysis finds reduced cardiovascular risk factors with liraglutide treatment

BiovaxID anticancer vaccine now available on a named-patient basis in Europe

Celera licenses five cancer-related targets to Bayer Schering Pharma

New phase I/II data presented on tremelimumab in metastatic melanoma

ADVANCE study shows reduced cardiovascular risk with Preterax in diabetes patients

Nicotinic alpha7 agonist from Arthrogen reduces experimental arthritis severity

Additional preclinical data on AMAP-102 encourage investigation in humans

Adventrx announces plans to submit an NDA for vinorelbine during second half of 2009

CytRx reports results from phase II trial of tamibarotene as third-line treatment for APL

Antitope and Vascular sign research agreement for therapeutic antibodies in vascular disease

Chugai reports results from phase III study of Epogin in chemotherapy-induced anemia

Photocure submits NDA to FDA for Hexvix in detection of papillary bladder cancer

Calixa commences phase II CXA-101 trial for complicated urinary tract infections

Wyeth and Catalyst to develop and commercialize factor VIIa products

Santhera reports results from phase IIb study of fipamezole in PD

European Commission grants marketing authorization for AstraZeneca's Iressa in NSCLC

Momenta reports results from phase II EMINENCE trial of M-118 in CAD

UCB and Biogen discontinue phase II clinical trial of CDP-323 in multiple sclerosis

European CHMP recommends marketing authorization for Tigenix's ChondroCelect

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.